Therapeutic use and profile of toxicity of the FOLFOX4 regimen

摘要: Abstract Introduction Since the publication of MOSAIC test results in 2004, FOLFOX4 regimen has been established as an adjuvant treatment which is recommended stage III colorectal cancer. The aim this study to assess use our field and describe its toxicity. Methods Descriptive treatments with prescribed between April 2005 March 2007. data was obtained from Farhos Oncologia® programme clinical records. following collected: age, gender, diagnosis, illness (TNM classification), adverse reactions, expressing severity according Common Toxicity Criteria 2.0. Results for 39 patients (24 men 15 women) average age 59. diagnoses were: 28 colon cancer (4 II, 17 III, 7 IV), 10 rectal (1 4 5 1 IV gastric most frequent reactions were peripheral neuropathy (82%), neutropaenia (56.4%), diarrhoea (53.9%). When completed, 9 continued active (average, 6.8 cycles). Of 30 remaining only 16 people completed 12 planned cycles. Forteen stopped their 8.1 cycles) due toxicity cases, progression 3 patient died. total 368 cycles administered, 68 suffered administration delays 22 had dosage reduced. Conclusion adjusted uses some solid scientific evidence, but limited made administering levels difficult.